Opexa Therapeutics Information

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

View Top Employees from Opexa Therapeutics

Website	http://www.opexatherapeutics.com/index.php
Ticker	OPXA
Revenue	$2.9 million
Funding	$18 million
Employees	23 (19 on RocketReach)
Founded	1986
Address	2635 Technology Forest Blvd, The Woodlands, Texas 77381, US
Phone	(281) 272-9331
Fax	(281) 272-1088
Technologies	JavaScript, HTML, PHP +12 more (view full list)
Industry	Biotechnology, Biotechnology Research, Healthcare, Pharmaceuticals, Science and Engineering, Medical, Health Care, Therapeutics
Web Rank	21 Million
Keywords	Opexa Therapeutics, Opx-212 Therapy For Nmo
Competitors	Anthera Pharmaceuticals, ChemoCentryx, Protalex, Inc., VGX Pharmaceuticals
SIC	SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies